Human interferon beta
- Generic Name
- Human interferon beta
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 74899-71-1
- Unique Ingredient Identifier
- V9GU1EM8SF
- Background
Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life.
...
- Indication
This drug is indicated to treat relapsing forms of Multiple Sclerosis (MS) in adults, which includes clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.
- Associated Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Associated Therapies
- -
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
- Conditions
- Interventions
- First Posted Date
- 2020-03-27
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Population Health Research Institute
- Target Recruit Count
- 6667
- Registration Number
- NCT04324463
- Locations
- 🇨🇦
Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada
🇧🇷Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil
🇨🇦London Health Sciences Centre, London, Ontario, Canada
Multiple Sclerosis: Chi3L1 and Treatment Efficacy
- First Posted Date
- 2020-02-28
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 63
- Registration Number
- NCT04289675
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2023-07-07
- Lead Sponsor
- Fundació Institut Germans Trias i Pujol
- Target Recruit Count
- 16
- Registration Number
- NCT02903537
- Locations
- 🇪🇸
ClÃnica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
- Conditions
- Interventions
- First Posted Date
- 2014-09-09
- Last Posted Date
- 2014-11-17
- Lead Sponsor
- Biogen
- Registration Number
- NCT02234869
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
- Conditions
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Faron Pharmaceuticals Ltd
- Target Recruit Count
- 37
- Registration Number
- NCT00789685
- Locations
- 🇬🇧
Western Infirmary, Glasgow, United Kingdom
🇬🇧University College London Hospital, London, United Kingdom
🇬🇧Whittington Hospital, London, United Kingdom
Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis
- Conditions
- Interventions
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 19
- Registration Number
- NCT00344253
- Locations
- 🇩🇪
Interdisciplinary Uveitis Center, University of Heidelberg, Heidelberg, Germany
Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 60
- Registration Number
- NCT00004450
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.